| http://www.w3.org/ns/prov#value | - The bill is a compromise between the House and Senate versions passed earlier and launches PDUFA IV. The bill retains six month exclusivity for pediatric studies, unless the drug is a blockbuster earning more than $1 billion, in which case it gets only 3.
|
